发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Recent developments in myeloid immune modulation in cancer therapy. 骨髓免疫调节在癌症治疗中的最新进展。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-09 DOI: 10.1016/j.trecan.2024.12.003
Sepideh Parvanian, Xinying Ge, Christopher S Garris
{"title":"Recent developments in myeloid immune modulation in cancer therapy.","authors":"Sepideh Parvanian, Xinying Ge, Christopher S Garris","doi":"10.1016/j.trecan.2024.12.003","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.12.003","url":null,"abstract":"<p><p>Myeloid cells play a crucial dual role in cancer progression and response to therapy, promoting tumor growth, enabling immune suppression, and contributing to metastatic spread. The ability of these cells to modulate the immune system has made them attractive targets for therapeutic strategies aimed at shifting their function from tumor promotion to fostering antitumor immunity. Therapeutic approaches targeting myeloid cells focus on modifying their numbers, genetics, metabolism, and interactions within the tumor microenvironment. These strategies aim to reverse their suppressive functions and redirect them to support antitumor immune responses by inhibiting immunosuppressive pathways, targeting specific receptors, and promoting their differentiation into less immunosuppressive phenotypes. Here, we discuss recent approaches to clinically target tumor myeloid cells, focusing on reprogramming myeloid cells to promote antitumor immunity.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence-based biomarkers for treatment decisions in oncology. 肿瘤治疗决策中基于人工智能的生物标志物。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-08 DOI: 10.1016/j.trecan.2024.12.001
Marta Ligero, Omar S M El Nahhas, Mihaela Aldea, Jakob Nikolas Kather
{"title":"Artificial intelligence-based biomarkers for treatment decisions in oncology.","authors":"Marta Ligero, Omar S M El Nahhas, Mihaela Aldea, Jakob Nikolas Kather","doi":"10.1016/j.trecan.2024.12.001","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.12.001","url":null,"abstract":"<p><p>The development of new therapeutic strategies such as immune checkpoint inhibitors (ICIs) and targeted therapies has increased the complexity of the treatment landscape for solid tumors. At the current rate of annual FDA approvals, the potential treatment options could increase by tenfold over the next 5 years. The cost of personalized medicine technologies limits its accessibility, thus increasing socioeconomic disparities in the treated population. In this review we describe artificial intelligence (AI)-based solutions - including deep learning (DL) methods for routine medical imaging and large language models (LLMs) for electronic health records (EHRs) - to support cancer treatment decisions with cost-effective biomarkers. We address the current limitations of these technologies and propose the next steps towards their adoption in routine clinical practice.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Embracing diversity: macrophage complexity in cancer. 拥抱多样性：巨噬细胞在癌症中的复杂性。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-02 DOI: 10.1016/j.trecan.2024.12.002
Jan Hochstadt, Sarai Martínez Pacheco, María Casanova-Acebes
{"title":"Embracing diversity: macrophage complexity in cancer.","authors":"Jan Hochstadt, Sarai Martínez Pacheco, María Casanova-Acebes","doi":"10.1016/j.trecan.2024.12.002","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.12.002","url":null,"abstract":"<p><p>Macrophages are myeloid cells that receive, integrate, and respond to tumoral cues. Tumors evolve and are shaped by macrophages, with tumor-associated macrophage (TAM)-tumor sculpting capacities going beyond an increase in their cellular mass. Longitudinal and local heterogeneity of TAM states is now possible with the use of single-cell and spatial transcriptomics. However, understanding TAM biology and its fundamental functional programs is still challenging, probably because of the lack of models that fully integrate TAM complexity. Here, we aim to review TAM diversity not only at the level of single-cell phenotypes but also by integrating complex physiological signals that determine their complexity and plasticity in tumors.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial DNA damage, repair, and replacement in cancer. 癌症中的线粒体 DNA 损伤、修复和替代。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-10-21 DOI: 10.1016/j.trecan.2024.09.010
Pavel Vodicka, Sona Vodenkova, Natalie Danesova, Ludmila Vodickova, Renata Zobalova, Kristyna Tomasova, Stepana Boukalova, Michael V Berridge, Jiri Neuzil
{"title":"Mitochondrial DNA damage, repair, and replacement in cancer.","authors":"Pavel Vodicka, Sona Vodenkova, Natalie Danesova, Ludmila Vodickova, Renata Zobalova, Kristyna Tomasova, Stepana Boukalova, Michael V Berridge, Jiri Neuzil","doi":"10.1016/j.trecan.2024.09.010","DOIUrl":"10.1016/j.trecan.2024.09.010","url":null,"abstract":"<p><p>Mitochondria are vital organelles with their own DNA (mtDNA). mtDNA is circular and composed of heavy and light chains that are structurally more accessible than nuclear DNA (nDNA). While nDNA is typically diploid, the number of mtDNA copies per cell is higher and varies considerably during development and between tissues. Compared with nDNA, mtDNA is more prone to damage that is positively linked to many diseases, including cancer. Similar to nDNA, mtDNA undergoes repair processes, although these mechanisms are less well understood. In this review, we discuss the various forms of mtDNA damage and repair and their association with cancer initiation and progression. We also propose horizontal mitochondrial transfer as a novel mechanism for replacing damaged mtDNA.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"62-73"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective autophagy receptor hinders antitumor immunity. 选择性自噬受体阻碍抗肿瘤免疫。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1016/j.trecan.2024.11.004
Jiao Liu, Rui Kang, Daolin Tang
{"title":"Selective autophagy receptor hinders antitumor immunity.","authors":"Jiao Liu, Rui Kang, Daolin Tang","doi":"10.1016/j.trecan.2024.11.004","DOIUrl":"10.1016/j.trecan.2024.11.004","url":null,"abstract":"<p><p>Autophagy has a dual role in tumor progression and therapy, influenced by specific receptors and cargo selection. Recent research published in Cell by Herhaus et al. identifies immunity-related GTPase Q (IRGQ) as a novel autophagy receptor that facilitates immune evasion in hepatocellular carcinoma (HCC) by degrading histocompatibility complex class I (MHC-I) molecules, highlighting a potential target to enhance immunotherapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"4-5"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors? 以癌症中的希波通路为靶点：肾毒性是 TEAD 抑制剂的一类效应？
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-11-08 DOI: 10.1016/j.trecan.2024.10.004
Sayantanee Paul, Jessica Sims, Trang Pham, Anwesha Dey
{"title":"Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?","authors":"Sayantanee Paul, Jessica Sims, Trang Pham, Anwesha Dey","doi":"10.1016/j.trecan.2024.10.004","DOIUrl":"10.1016/j.trecan.2024.10.004","url":null,"abstract":"<p><p>The Hippo pathway has emerged as a critical player in both cancers and targeted therapy resistance. Recent drug discovery efforts have led to the development of TEAD inhibitors, several of which have already progressed to the clinic. To truly leverage their potential as anticancer therapeutics, safety considerations, particularly in regard to the kidney, warrant additional investigation. This review explores the Hippo pathway's role in cancers, its therapeutic potential, role in kidney development, and the need to evaluate the best strategies to translate its clinical application for long-term patient benefit.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"25-36"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in LAG3 cancer immunotherapeutics. LAG3 癌症免疫疗法的进展。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.1016/j.trecan.2024.10.009
Kieran Adam, Samuel C Butler, Creg J Workman, Dario A A Vignali
{"title":"Advances in LAG3 cancer immunotherapeutics.","authors":"Kieran Adam, Samuel C Butler, Creg J Workman, Dario A A Vignali","doi":"10.1016/j.trecan.2024.10.009","DOIUrl":"10.1016/j.trecan.2024.10.009","url":null,"abstract":"<p><p>Cancer treatment has entered the age of immunotherapy. Immune checkpoint inhibitor (ICI) therapy has shown robust therapeutic potential in clinical practice, with significant improvements in progression-free survival (PFS) and overall survival (OS). Recently, checkpoint blockade of the lymphocyte activation gene 3 (LAG3) inhibitory receptor (IR) in combination with programmed death protein 1 (PD1) inhibition has been FDA approved in patients with advanced melanoma. This has encouraged the clinical evaluation of new LAG3-directed biologics in combination with other checkpoint inhibitors. Several of these studies are evaluating bispecific antibodies that target exhausted T (T<sub>EX</sub>) cells expressing multiple IRs. This review discusses the current understanding of LAG3 in regulating antitumor immunity and the ongoing clinical testing of LAG3 inhibition in cancer.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"37-48"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aberrant nuclei with amplified DNA in cancer. 癌症中DNA扩增的异常细胞核。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-10-06 DOI: 10.1016/j.trecan.2024.09.005
Venkata Narasimha Kadali, Ofer Shoshani
{"title":"Aberrant nuclei with amplified DNA in cancer.","authors":"Venkata Narasimha Kadali, Ofer Shoshani","doi":"10.1016/j.trecan.2024.09.005","DOIUrl":"10.1016/j.trecan.2024.09.005","url":null,"abstract":"<p><p>Gene amplification in the form of extrachromosomal DNA (ecDNA) or intrachromosomal homogenous staining regions (HSRs) is an emerging hallmark in cancer. Recent studies implicate abnormal nuclear structures in the biogenesis and evolution of amplified DNA. Here, we discuss how the interplay between aberrant nuclei and gene amplification drives cancer therapy resistance and metastasis.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"9-11"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer researchers as storytellers for the lay public. 癌症研究人员为普通公众讲故事。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-09-27 DOI: 10.1016/j.trecan.2024.09.004
William G Nelson
{"title":"Cancer researchers as storytellers for the lay public.","authors":"William G Nelson","doi":"10.1016/j.trecan.2024.09.004","DOIUrl":"10.1016/j.trecan.2024.09.004","url":null,"abstract":"<p><p>Cancer researchers tend to be well-versed in communicating research and research results to scientific audiences. To maintain momentum and progress against cancer, they must acquire and nurture skills allowing for better engagement with the lay public.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"6-8"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology. DNA 错配修复蛋白的非修复功能：精准肿瘤学的新途径。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-01-01 Epub Date: 2024-10-28 DOI: 10.1016/j.trecan.2024.10.001
Jerry Tyler DeWitt, Megha Raghunathan, Svasti Haricharan
{"title":"Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology.","authors":"Jerry Tyler DeWitt, Megha Raghunathan, Svasti Haricharan","doi":"10.1016/j.trecan.2024.10.001","DOIUrl":"10.1016/j.trecan.2024.10.001","url":null,"abstract":"<p><p>DNA damage repair (DDR) proteins are well recognized as guardians of the genome that are frequently lost during malignant transformation of normal cells across cancer types. To date, their tumor suppressor functions have been generally regarded as a consequence of their roles in maintaining genomic stability: more genomic instability increases the risk of oncogenic transformation events. However, recent discoveries centering around DNA mismatch repair (MMR) proteins suggest a broader impact of the loss of DDR proteins on cellular processes beyond genomic instability. Here, we explore the clinical implications of nonrepair roles for DDR proteins, using the growing evidence supporting roles for DNA MMR proteins in cell cycle and apoptosis regulation, metabolic function, the cellular secretome, and immunomodulation.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"49-61"},"PeriodicalIF":14.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信